Mithra Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Mithra Pharmaceuticals's earnings have been declining at an average annual rate of -24.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 7.8% per year.
Key information
-24.2%
Earnings growth rate
-17.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -7.8% |
| Return on equity | -258.1% |
| Net Margin | -426.0% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Mithra Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 22 | -93 | 16 | 76 |
| 31 Mar 22 | 22 | -105 | 15 | 81 |
| 31 Dec 21 | 23 | -117 | 14 | 85 |
| 30 Sep 21 | 21 | -115 | 15 | 86 |
| 30 Jun 21 | 19 | -113 | 16 | 87 |
| 31 Mar 21 | 14 | -103 | 17 | 83 |
| 31 Dec 20 | 9 | -92 | 17 | 78 |
| 30 Sep 20 | 44 | -31 | 17 | 71 |
| 30 Jun 20 | 79 | 29 | 16 | 64 |
| 31 Mar 20 | 88 | 1 | 16 | 61 |
| 31 Dec 19 | 97 | -27 | 16 | 57 |
| 30 Sep 19 | 84 | -54 | 15 | 47 |
| 30 Jun 19 | 71 | -82 | 14 | 37 |
| 31 Mar 19 | 64 | -55 | 12 | 36 |
| 31 Dec 18 | 58 | -28 | 11 | 36 |
| 30 Sep 18 | 46 | -41 | 10 | 39 |
| 30 Jun 18 | 33 | -53 | 10 | 42 |
| 31 Mar 18 | 33 | -46 | 10 | 45 |
| 31 Dec 17 | 32 | -38 | 10 | 48 |
| 30 Sep 17 | 26 | -37 | 12 | 46 |
| 30 Jun 17 | 20 | -36 | 13 | 43 |
| 31 Mar 17 | 21 | -36 | 14 | 39 |
| 31 Dec 16 | 22 | -35 | 16 | 34 |
| 30 Sep 16 | 21 | -29 | 17 | 29 |
| 30 Jun 16 | 20 | -23 | 19 | 24 |
| 31 Mar 16 | 20 | -16 | 17 | 17 |
| 31 Dec 15 | 20 | -10 | 15 | 9 |
Quality Earnings: MITP.F is currently unprofitable.
Growing Profit Margin: MITP.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MITP.F is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.
Accelerating Growth: Unable to compare MITP.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MITP.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: MITP.F has a negative Return on Equity (-258.07%), as it is currently unprofitable.